Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to ...

An experimental obesity drug ... of medication adherence, weight loss results were 13.7% with CagriSema and 3.4% with the placebo. Although the trial results failed to meet Novo Nordisk's ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

In the REDEFINE 2 trial, CagriSema led to 15.7% weight loss after 68 weeks, compared to 3.1% with placebo, with 89.7% achieving at least 5% Novo Nordisk plans to seek regulatory approval for ...

Shares of Novo ... approval for CagriSema in the first quarter of 2026. Shares of U.S. rival Eli Lilly, which makes weight-loss drug Mounjaro, briefly jumped higher after Novo Nordisk's update ...

Novo Nordisk still has two more Phase 3 trials scheduled for CagriSema, and said Monday it still expects to submit the drug for regulatory approval ... its current weight loss drugs, and are ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss ... drug compared to the company's other drugs, Ozempic, which is approved ...

Compound drugs are copies of U.S. Food and Drug Administration-approved medications ... drug for weight loss after being denied by insurance Both Eli Lilly and Novo Nordisk now also offer ...